Perrigo Company plc (PRGO) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 138.77M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 138.77M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 138.77M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 138.77M | (m) | (m) |
| 2026-03-31 | 138.37M | (m) | (m) |
| 2025-09-30 | 137.62M | (m) | (m) |
| 2025-06-30 | 137.58M | (m) | (m) |
| 2025-03-31 | 137.48M | (m) | (m) |
| 2024-12-31 | 136.46M | (m) | (m) |
| 2024-09-30 | 136.43M | (m) | (m) |
| 2024-06-30 | 136.42M | (m) | (m) |
| 2024-03-31 | 136.32M | (m) | (m) |
| 2023-09-30 | 135.51M | (m) | (m) |
| 2023-06-30 | 135.40M | (m) | (m) |
| 2023-03-31 | 135.33M | (m) | (m) |
| 2022-12-31 | 134.65M | (m) | (m) |
| 2022-09-30 | 134.64M | (m) | (m) |
| 2022-06-30 | 134.62M | (m) | (m) |
| 2022-03-31 | 134.55M | (m) | (m) |
| 2021-12-31 | 133.78M | (m) | (m) |
| 2021-09-30 | 133.77M | (m) | (m) |
| 2021-06-30 | 133.71M | (m) | (m) |
| 2021-03-31 | 133.55M | (m) | (m) |
| 2020-12-31 | 133.10M | (m) | (m) |
| 2020-09-30 | 136.49M | (m) | (m) |
| 2020-06-30 | 136.48M | (m) | (m) |
| 2020-03-31 | 136.31M | (m) | (m) |
| 2019-09-30 | 136.11M | (m) | (m) |
| 2019-06-30 | 136.05M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |